n | % | ||
No. of patients | 19 | ||
Pt age (yr) | Median (Range) | 65 (51 - 79) | |
No. ECOG performance status | 0 | 13 | 68.4 |
1 | 4 | 21.1 | |
2 | 2 | 10.5 | |
Gleason score at diagnosis | ≤6 | 2 | 10.5 |
7 | 2 | 10.5 | |
≥8 | 14 | 73.7 | |
unknown | 1 | 5.3 | |
Baseline PSA before DEC (ng/mL) | Median (Range) | 67.0 (9.1 - 1102) | |
Median time from diagnosis to ADT (m) | Median (Range) | 1.0 (0.0 - 1062) | |
Median time from diagnosis to docetaxel (m) | Median (Range) | 27.0 (3.0 - 1313) | |
Median time from DP to DEC (m) | Median (Range) | 13.0 (4.0 - 29.0) | |
Median time from CRPC to DEC (m) | Median (Range) | 17.0 (5.0 - 57.0) | |
Median cycles of docetacel before DEC | 6 (1 - 12) | ||
Metastatic site | Bone | 18 | 94.7 |
Lymph nodes | 13 | 68.4 | |
Visceral | 5 | 26.3 | |
Other | 1 | 5.3 | |
Prior therapy | Surgery | 4 | 21.1 |
Radiation | 2 | 10.5 | |
Medical castration | 15 | 78.9 | |
Surgical castration | 4 | 21.1 | |
Bicalutamide | 19 | 100.0 | |
Flutamide | 12 | 63.2 | |
Chlormadinone acetate | 3 | 15.8 | |
EMP | 16 | 84.2 | |
Other | 2 | 10.5 |